aTyr Pharma cuts 60% of workforce to fund second Phase III study of efzofitimod in pulmonary sarcoidosis

The restructuring concentrates aTyr’s resources on a new late-stage study in patients with restrictive lung disease after its first Phase III trial missed its primary endpoint.

aTyr Pharma is reducing its workforce by approximately 60% and prioritising resources towards a second Phase III study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

The strategy narrows development to a subgroup in which post hoc analysis of the previous EFZO-FIT study suggested improvements in lung function and patient-reported outcomes, although those findings require prospective confirmation in the new trial.

Field	Content
Alert Type	Industry Update
Topic	Workforce restructuring; clinical development strategy
Organisation(s)	aTyr Pharma
Affected Stakeholders	aTyr Pharma employees; investors; clinical-development teams; investigators and patients involved in the efzofitimod programme
Therapy Area(s)	Pulmonology; Interstitial lung disease; Pulmonary sarcoidosis
Geography	United States; global clinical development
What Happened	In August 2026, aTyr Pharma announced a restructuring involving an approximately 60% reduction in its workforce as it focuses resources on a new Phase III study of efzofitimod in pulmonary sarcoidosis. The decision follows the September 2025 Phase III EFZO-FIT trial, which failed to meet its primary endpoint of reducing oral corticosteroid use versus placebo. Following a Type C meeting with the FDA, aTyr decided to pursue another Phase III study in a narrower population of patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The company submitted the planned study protocol to the FDA in June 2026. (aTyr Pharma)
Why It Matters	The restructuring illustrates the financial and development consequences of pursuing a second pivotal programme after an unsuccessful Phase III trial. Rather than abandoning efzofitimod, aTyr is concentrating capital on a more narrowly defined pulmonary sarcoidosis population identified through analysis of EFZO-FIT, making the next trial critical to the future of its lead programme.
Supporting Context	EFZO-FIT enrolled 268 patients and missed its primary steroid-reduction endpoint in September 2025. Subsequent analysis identified a subgroup of 44 patients with restrictive lung disease in whom the 5 mg/kg dose was associated with improvements in forced vital capacity and several patient-reported outcomes versus placebo; because this was a post hoc subgroup analysis, the findings do not establish efficacy and require prospective validation. (aTyr Pharma)
Who Is Most Affected	aTyr employees are directly affected by the 60% workforce reduction, while the company’s clinical-development organisation is becoming more concentrated around efzofitimod. Patients and investigators in pulmonary sarcoidosis are also relevant because the programme is continuing with a substantially narrower target population rather than being discontinued after the original Phase III result.
Industry Impact	aTyr’s strategy provides an example of a biotech using subgroup findings and regulatory discussions to redesign a pivotal programme following a Phase III miss. The approach carries significant development risk because the apparent benefit in restrictive lung disease was identified retrospectively and must now be demonstrated prospectively.
Key Takeaway	aTyr is making a substantial workforce reduction to preserve resources for a second attempt to establish efzofitimod’s efficacy in a more narrowly defined pulmonary sarcoidosis population.
What to Watch	The FDA’s response to the new Phase III protocol, initiation and financing of the study, and whether the prospective trial confirms the lung-function and patient-reported outcome signals observed in the restrictive-disease subgroup of EFZO-FIT. (aTyr Pharma)
Primary Source	aTyr Pharma corporate announcement and regulatory disclosures
Relevant Date	August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com